File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Osteoporosis: Treatment and risk assessment

TitleOsteoporosis: Treatment and risk assessment
Authors
Baqir, WCopeland, CWorsley, A
Issue Date2009
Citation
Clinical Pharmacist, 2009, v. 1 n. 5, p. 216-223 How to Cite?
AbstractPharmacological management of osteoporosis includes use of calcium with vitamin D, bisphosphonates, strontium ranelate and hormonal therapies. This article discusses these treatment options and the role pharmacists have in supporting patients with or at risk of developing the disease. It also looks at national guidelines for treatment and prevention of osteoporosis. Current technology appraisals from the National Institute for Health and Clinical Excellence look specifically at primary and secondary prevention for postmenopausal women only. The National Osteoporosis Guideline Group guideline for postmenopausal women and men aged over 50 years provides recommendations for the management of those at high risk of fracture by using a probability assessment tool.
Persistent Identifierhttp://hdl.handle.net/10722/171443
ISSN
1758-9061
2020 SCImago Journal Rankings: 0.126
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorBaqir, Wen_US
dc.contributor.authorCopeland, Cen_US
dc.contributor.authorWorsley, Aen_US
dc.date.accessioned2012-10-30T06:14:16Z-
dc.date.available2012-10-30T06:14:16Z-
dc.date.issued2009en_US
dc.identifier.citationClinical Pharmacist, 2009, v. 1 n. 5, p. 216-223en_US
dc.identifier.issn1758-9061en_US
dc.identifier.urihttp://hdl.handle.net/10722/171443-
dc.description.abstractPharmacological management of osteoporosis includes use of calcium with vitamin D, bisphosphonates, strontium ranelate and hormonal therapies. This article discusses these treatment options and the role pharmacists have in supporting patients with or at risk of developing the disease. It also looks at national guidelines for treatment and prevention of osteoporosis. Current technology appraisals from the National Institute for Health and Clinical Excellence look specifically at primary and secondary prevention for postmenopausal women only. The National Osteoporosis Guideline Group guideline for postmenopausal women and men aged over 50 years provides recommendations for the management of those at high risk of fracture by using a probability assessment tool.en_US
dc.languageengen_US
dc.relation.ispartofClinical Pharmacisten_US
dc.titleOsteoporosis: Treatment and risk assessmenten_US
dc.typeArticleen_US
dc.identifier.emailWorsley, A:alanwor@hku.hken_US
dc.identifier.authorityWorsley, A=rp01395en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-84861731874en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84861731874&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume1en_US
dc.identifier.issue5en_US
dc.identifier.spage216en_US
dc.identifier.epage223en_US
dc.identifier.scopusauthoridBaqir, W=6505947970en_US
dc.identifier.scopusauthoridCopeland, C=36522653100en_US
dc.identifier.scopusauthoridWorsley, A=16445153200en_US
dc.identifier.issnl1758-9061-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats